ARA-290 10mg

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the B-helix of erythropoietin (EPO) that activates the innate repair receptor (IRR), a heterodimer of EPO receptor and beta common receptor (betacR). Unlike EPO itself, ARA-290 does not bind the classical EPO receptor homodimer responsible for erythropoiesis, so it does not stimulate red blood cell production or carry the associated thrombotic risks. The innate repair receptor is expressed on a variety of cell types including neurons, endothelial cells, and immune cells, particularly in response to tissue damage and inflammation. Activation of the IRR by ARA-290 triggers anti-apoptotic signaling (PI3K/Akt and JAK2/STAT5 pathways), reduces inflammatory cytokine production, and promotes tissue repair. This tissue-protective activity was first recognized when EPO was shown to have neuroprotective effects independent of its hematopoietic function. ARA-290 has advanced through multiple Phase II clinical trials for diabetic neuropathy, sarcoidosis-related neuropathy, and chronic pain. Brines et al. demonstrated improvements in small nerve fiber regeneration in patients with sarcoid neuropathy, and subsequent studies showed improved corneal nerve density and reduced neuropathic pain in diabetic patients.

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the B-helix of erythropoietin (EPO) that activates the innate repair receptor (IRR), a heterodimer of EPO receptor and beta common receptor (betacR). Unlike EPO itself, ARA-290 does not bind the classical EPO receptor homodimer responsible for erythropoiesis, so it does not stimulate red blood cell production or carry the associated thrombotic risks. The innate repair receptor is expressed on a variety of cell types including neurons, endothelial cells, and immune cells, particularly in response to tissue damage and inflammation. Activation of the IRR by ARA-290 triggers anti-apoptotic signaling (PI3K/Akt and JAK2/STAT5 pathways), reduces inflammatory cytokine production, and promotes tissue repair. This tissue-protective activity was first recognized when EPO was shown to have neuroprotective effects independent of its hematopoietic function. ARA-290 has advanced through multiple Phase II clinical trials for diabetic neuropathy, sarcoidosis-related neuropathy, and chronic pain. Brines et al. demonstrated improvements in small nerve fiber regeneration in patients with sarcoid neuropathy, and subsequent studies showed improved corneal nerve density and reduced neuropathic pain in diabetic patients.

Clinical trials used 2-4 mg SC daily or three times weekly. Neuropathy studies used 4 mg SC for 28 days. Animal neuroprotection studies used 10-30 mcg/kg.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.